Therapeutic Results of the Treatment Brain Tumors Using Radiosurgery and Stereotactic Radiotherapy
Authors:
H. Doleželová 1; L. Hynková 1; P. Pospíšil 1; T. Kazda 1; P. Šlampa 1; I. Čoupková 1; I. Šiková 2; P. Fardus 3; T. Svoboda 4; J. Garčic 5; M. Vrzal 5; I. Selingerová 6; I. Horová 6
Authors‘ workplace:
Klinika radiační onkologie LF MU a MOÚ Brno
1; Neurologická ambulance MOÚ Brno
2; Neurochirurgická klinika LF MU a FN Brno
3; Klinika komplexní onkologické péče LF MU a MOÚ Brno
4; Oddělení radiologické fyziky MOÚ Brno
5; Ústav matematiky a statistiky PřF MU Brno
6
Published in:
Klin Onkol 2012; 25(6): 445-451
Category:
Original Articles
Práce byla podpořena Evropským fondem pro regionální rozvoj a státním rozpočtem České republiky (OP VaVpI – RECAMO, CZ.1.05/2.1.00/03.0101).
Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.
Overview
Background:
We reviewed the results of treatment of patiens treated with stereotactic radiation methods in our department.
Material and methods:
Patients with primary brain tumor or brain metastases underwent CT and MR examination. Then they were treated on X knife in the Clinic of Radiation Oncology in Masaryk Memorial Cancer Institute Brno.
Results:
A total of 101 patients with primary brain tumors underwent stereotactic treatment. These were mainly meningeomas, high-grade gliomas and low-grade gliomas. In 37% of cases patients underwent reiradiation. Stereotactic radiosurgery was applied with a median dose of 18 Gy. Hypofrakcionated stereotactic radiotherapy was applied at a doses of mostly 5 × 5 Gy. Total toxicity of treatment was low: 8% acute G1, late toxicity in 1% of cases. In the whole group achieved partial remission 10 patients (9,9%). One patient had complete remission (0,99%). It was a diagnosis of pituitary adenoma. In 69 patients stable disease was observed (68,3%) and 12 patients had progression (11,88%). Median follow up the entire group was 22,4 months. A statistically significant difference in survival was found in the comparison of different diagnosis, patiens who recieved prior radiotherapy and patiens without previous irradiation. Another significant difference in survival was observed compared to patients treated with stereotactic treatment or stereotactic radiosurgery and the size of the tumor volume larger / smaller 10 cm3. In the group with brain metastases there were 56 patients. In 10% of cases preceded radiotherapy neurosurgical performance. Twenty four patients underwent cranial irradiation entire dose of 30 Gy. Median stereotactic radiosurgery dose was 20 Gy, the application of stereotactic treatment were mostly of 5 × 5 Gy. G1 acute toxicity occurred in 2 patients (3.8%), grade G2 in one patient (1.9%). Late toxicity was observed in 2 patients (one G1 and one G3). Complete remission was achieved in 4 patients (7.1%), partial remission in 27 patients (48.2%), stable disease in 9 (16.1%) and progression was observed in 5 patients (8.9%). Median follow-up the entire group was 13.3 months. There was no statistically significant difference in survival with respect to gender, age, KI, irradiation of the whole brain or type of treatment used. Patients who have undergone neurosurgery prior to irradiation had no difference in survival compared to patients without surgery, but the time to progression was significantly longer (p = 0.016).
Conclusion:
Stereotactic radiation methods are part of modern radiotherapy. Their indication is necessary to consider with regard to the benefit of the patient. Quality equipment radiotherapy department and trained personnel are the condition for their correct using.
Key words:
radiosurgery – brain neoplasms – locoregional neoplasm recurrence – stereotactic radiotherapy
Sources
1. National Comprehensive Cancer Network [online]. www.NCCN.org
2. Šlampa P a kol. Radiační onkologie v praxi. 3. vyd. Brno: Masarykův onkologický ústav 2011: 201–225.
3. Šimonová G, Novotný J jr. Stereotaktická radiochirurgie a radioterapie. S. 413–425 V: Šlampa P, Petera J: Radiační onkologie. Praha: Galén 2007: 413–426.
4. Liščák R a kol. Radiochirurgie gamanožem. Principy a neurochirurgické aplikace. Praha: Grada 2009: 77–92.
5. Collet D. Modelling survival datat in medici research. Chapman and Hall/CRC 1999.
6. El Majdoub F, Elawady M, Bührle C et al. µMLC-LINAC radiosurgery for intracranial meningeomas: of komplex shape. Acta Neurochir (Wien) 2012; 154(4): 599–604.
7. Pollock BE, Stafford SL, Link MJ et al. Single-fraction Radiosurgery for Presumed Intracranial Meningiomas: Efficacy and Complications from a 22-Year Experience. Int J Radiat Oncol Biol Phys 2012; 83(5): 1414–1418.
8. Attia A, Chan MD, Mott RT et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol 2012; 108(1): 179–185.
9. Minniti G, Amicheti M, Enrici RM et al. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 2009; 4: 42.
10. Metellus P, Regis J, Muracciole X et al. Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy. Neurosurgery 2005; 57(5): 873–886.
11. Torres RC, Frighetto L, De Salles AA et al. Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus 2003; 14(5): e5.
12. Lo SS, Cho KH, Hall WA et al. Single dose versus fractionated stereotactic radiotherapy for meningiomas. Can J Neurol Sci 2002; 29(3): 240–248.
13. Lakomý R, Fadrus P, Šlampa P et al. Výsledky multimodální léčby glioblastoma multiforme: Konsekutivní série 86 pacientů diagnostikovaných v letech 2003–2009. Klin Onkol 2011; 24(2): 112–120.
14. Biswas T, Okunieff P, Schell MC et al. Stereotactic radiosurgery for glioblastoma. Retospective analysis. Radiat Oncol 2009, 4: 11.
15. Kong DS, LeeJI, Park K. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignit gliomas. Cancer 2008; 112(9): 2046–2051.
16. Fokas E, Wacker U, Gross MW et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009; 185(4): 235–240.
17. Ernst-Stecken A, Ganslandt O, Lambrecht et al. Survival and quality of life after hypofactionated stereotacitc radiotherapy for recurrent malignit glioma. J Neurooncol 2007: 81(3): 287–294.
18. Henke G, Paulsen F, Steinbach JP et al. Hypofractionated reiradiation for recurrent malignit glioma. Strahlenther Onkol 2009; 185(2): 113–119.
19. Mentha MP, Tsao MN, Whelan TJ et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005; 63(1): 37–46.
20. Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet Oncology 2009; 10(11): 1037–1044.
21. Sanghavi SN, Miranpuri SS, Chappell R et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001; 51(2): 426–434.
22. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295(21): 2483–2491.
23. Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncology 2009; 10(11): 1037–1044.
24. Simonova G, Liscak R. Radiosurgery of brain metastases usisng Leskell gamma knife – results of 400 treated patiens. ECCO poster 2011. DOI:10.1016/S0959-8049(11)72291-2.
25. Chorváth M, Bolješíková E. Metastázy do centrálního nervového systému. In: Jurga Ľ et al (ed). Klinická a radiačná onkológia. 1. vyd. Martin: Osveta 2010: 1309–1315.
26. Ellis TL, Neal MT, Chan MD et al. The role of Surgery, Radiotherapy and Whole Brain Radiation Therapy in the Management of Patients with Metastatic Brain Tumors. Int J Surg Oncol 2012; 2012: 952345.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 6
Most read in this issue
- Liver Function Assessment in Oncology Practice
- Cost Analysis of XELOX and FOLFOX-4 Chemotherapy Regimens for Colorectal Carcinoma
- Incidentally Discovered White Subcupsular Liver Nodules during Laparoscopic Surgery: Biliary Hamartoma and Peribiliary Gland Hamartoma
- A Case Report: Patient with Advanced Ovarial Tumour and Supporting Care